| abstract |
The compounds are Tankirase inhibitors and can be used, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. Claim 1: Compounds of the formula (1) wherein: R¹, R² each denote, independently of each other, H, F or Cl; R³ denotes H, F, Cl, CH₃ or OCH₃; X¹, X² each denote, independently of each other, CH or N; And denotes A, Cyc or oxyranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl or diazepanyl, which may not be substituted or which may be mono- or disubstituted with = O, Hal, OH and / or A ; A denotes unbranched or branched C₁₋₄ alkyl, wherein a CH₂ group may be replaced by an O atom and / or an H atom may be replaced by OH; A denotes unbranched or branched C₂₋₁₀ alkyl, wherein two adjacent carbon atoms may form a double bond and / or one or two non-adjacent CH and / or CH₂ groups may be replaced by atoms of N, O and / or S and wherein 1-7 atoms of H may be replaced by F, Cl and / or OH; Cyc denotes C₃₋₇ cycloalkyl, which is unsubstituted or which is monosubstituted with OH, Hal or A; Hal denotes F, Cl, Br or I; provided that at least one of R¹, R², R³ is not H, and provided that Y is not 4-isopropyl-1-piperazinyl, and its pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures in all proportions. |